(-0.53%) 5 080.50 points
(-0.36%) 38 539 points
(-0.84%) 17 517 points
(-0.17%) $82.67
(-0.12%) $1.651
(0.00%) $2 338.30
(0.14%) $27.39
(0.21%) $917.70
(-0.24%) $0.932
(-0.30%) $10.95
(-0.41%) $0.799
(-0.11%) $92.22
Live Chart Being Loaded With Signals
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally...
Stats | |
---|---|
Today's Volume | 294 500 |
Average Volume | 119 788 |
Market Cap | 635.93M |
EPS | HKD0 ( 2024-03-26 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -0.870 |
ATR14 | HKD0.0150 (1.22%) |
Genor Biopharma Holdings Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Genor Biopharma Holdings Financials
Annual | 2023 |
Revenue: | HKD0 |
Gross Profit: | HKD0 (0.00 %) |
EPS: | HKD-1.330 |
Q4 | 2023 |
Revenue: | HKD0 |
Gross Profit: | HKD0 (0.00 %) |
EPS: | HKD-0.390 |
Q3 | 2023 |
Revenue: | HKD0 |
Gross Profit: | HKD0 (0.00 %) |
EPS: | HKD-0.390 |
Q2 | 2023 |
Revenue: | HKD0 |
Gross Profit: | HKD-31.38M (0.00 %) |
EPS: | HKD-0.270 |
Financial Reports:
No articles found.
Genor Biopharma Holdings
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB265, and GB 266 for the treatment of cancer. Genor Biopharma Holdings Limited was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators